- Home
- SRG vs ABEO Comparison
SRG vs ABEO Comparison
Compare SRG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | ABEO |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.5M | 307.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SRG | ABEO |
|---|---|---|
| Price | $2.64 | $5.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 242.5K | ★ 979.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.31 | $4.00 |
| 52 Week High | $4.56 | $7.54 |
Technical Indicators
Market Signals| Indicator | SRG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 51.79 |
| Support Level | $2.61 | $5.24 |
| Resistance Level | $2.80 | $5.64 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 36.36 | 61.72 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.